Gilead Sciences stock at EUR 151.97, up 1.21% premarket
Published on 11/09/2026 at 08:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey Business Drivers
- Gilead Sciences is a global biopharmaceutical company focused on medicines for critical health needs.
- The company operates across the United States, Europe and other international markets.
- Its portfolio covers treatments for severe conditions including HIV/AIDS, liver disease, cancer and hematological disorders.
Gilead Sciences stock traded at 151.97 euros on Lang & Schwarz at 08:06 CET on Monday, November 9, 2026, 1.21 percent above the Xetra close of Friday, November 6, at 150.16 euros.
Gilead Sciences is a global biopharmaceutical company focused on medicines for critical health needs, according to its company profile. Its operations span the United States, Europe and other international markets, with treatments covering areas including HIV/AIDS, liver disease, cancer and hematological disorders.
Pipeline Remains In Focus
Recent Livdelzi data and a scheduled Wolfe Research Healthcare Conference appearance have put Gilead's development pipeline in focus for the week.
Investors can follow the real-time quote of Gilead Sciences stock during the session.
The broader market backdrop is tracked through the S&P 500.
